138 related articles for article (PubMed ID: 11536301)
1. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.
Burchardt M; Burchardt T; Shabsigh A; Ghafar M; Chen MW; Anastasiadis A; de la Taille A; Kiss A; Buttyan R
Prostate; 2001 Sep; 48(4):225-30. PubMed ID: 11536301
[TBL] [Abstract][Full Text] [Related]
2. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
4. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
5. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
6. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
7. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
8. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
9. Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo.
Kajiwara T; Takeuchi T; Ueki T; Moriyama N; Ueki K; Kakizoe T; Kawabe K
Int J Urol; 1999 Oct; 6(10):520-5. PubMed ID: 10533903
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer.
Singh S; Sadacharan S; Su S; Belldegrun A; Persad S; Singh G
Cancer Res; 2003 May; 63(9):2306-11. PubMed ID: 12727854
[TBL] [Abstract][Full Text] [Related]
11. Expression of androgen receptor is negatively regulated by p53.
Alimirah F; Panchanathan R; Chen J; Zhang X; Ho SM; Choubey D
Neoplasia; 2007 Dec; 9(12):1152-9. PubMed ID: 18084622
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
14. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
[TBL] [Abstract][Full Text] [Related]
15. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
18. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells.
Chen MW; Vacherot F; De La Taille A; Gil-Diez-De-Medina S; Shen R; Friedman RA; Burchardt M; Chopin DK; Buttyan R
Oncogene; 2002 Nov; 21(51):7861-71. PubMed ID: 12420223
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
Igawa T; Lin FF; Lee MS; Karan D; Batra SK; Lin MF
Prostate; 2002 Mar; 50(4):222-35. PubMed ID: 11870800
[TBL] [Abstract][Full Text] [Related]
20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
